Immunocore (IMCR) Stock Forecast & Price Target

$31.40

+0.63 (+2.05%)

(As of 09/27/2024 08:51 PM ET)

Immunocore - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 12 Analyst Ratings

Sell
0

Hold
1

Buy
11

Based on 12 Wall Street analysts who have issued ratings for Immunocore in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 1 has given a hold rating, and 11 have given a buy rating for IMCR.

Consensus Price Target

$80.40
156.05% Upside

According to the 12 analysts' twelve-month price targets for Immunocore, the average price target is $80.40. The highest price target for IMCR is $100.00, while the lowest price target for IMCR is $66.00. The average price target represents a forecasted upside of 156.05% from the current price of $31.40.

Get the Latest News and Ratings for IMCR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Immunocore and its competitors.

IMCR Analyst Ratings Over Time

Type	Current Forecast 10/1/23 to 9/30/24	1 Month Ago 9/1/23 to 8/31/24	3 Months Ago 7/3/23 to 7/2/24	1 Year Ago 10/1/22 to 10/1/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	11 Buy rating(s)	13 Buy rating(s)	12 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$80.40	$80.70	$81.85	$71.38
Forecasted Upside	156.05% Upside	124.92% Upside	135.19% Upside	37.54% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

⭕ [URGENT] Buy Alert just triggered (Ad)

My absolute favorite stock just hit a critical "buy now" trigger price.

Click here for the ticker >>>

IMCR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IMCR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Immunocore Stock vs. The Competition

Type	Immunocore	Medical Companies	S&P 500
Consensus Rating Score	2.92	2.78	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	156.05% Upside	818.78% Upside	6.16% Upside
News Sentiment Rating	Neutral News See Recent IMCR News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/17/2024	Needham & Company LLC 2 of 5 stars		Lower Target	Buy ➝ Buy	$81.00 ➝ $78.00	+136.36%
9/17/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00	+203.03%
9/9/2024	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Overweight
8/9/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$87.00 ➝ $89.00	+131.35%
8/9/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$92.00 ➝ $66.00	+74.05%
7/10/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$70.00 ➝ $66.00	+73.68%
Get the Latest News and Ratings for IMCR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Immunocore and its competitors with MarketBeat's FREE daily newsletter.
5/13/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$90.00 ➝ $88.00	+49.43%
5/9/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$63.00 ➝ $67.00	+12.25%
4/29/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Chang Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/29/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$74.00	+26.58%
4/23/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$92.00	+61.63%
10/31/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$84.00	+91.87%
8/16/2023	Capital One Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$84.00	+39.42%
8/11/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$85.00 ➝ $91.00	+48.89%
7/31/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$79.00	+20.45%
3/24/2023	Bryan, Garnier & Co Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$16.00	-66.22%
12/16/2022	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$33.00 ➝ $80.00	+34.63%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 01:21 AM ET.

IMCR Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Immunocore is $80.40, with a high forecast of $100.00 and a low forecast of $66.00.
: 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunocore in the last twelve months. There is currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IMCR shares.
: According to analysts, Immunocore's stock has a predicted upside of 156.05% based on their 12-month stock forecasts.
: Immunocore has been rated by research analysts at Barclays, Cantor Fitzgerald, HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, and Oppenheimer in the past 90 days.
: Analysts like Immunocore more than other "medical" companies. The consensus rating score for Immunocore is 2.92 while the average consensus rating score for "medical" companies is 2.78. Learn more on how IMCR compares to other companies.